The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
The acquisition combines Firstsource’s market-leading AI and automation capabilities with TeleMedik’s operational footprint in Puerto Rico
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The company previously completed a $150 million venture investment, acquisition, and recapitalization
Subscribe To Our Newsletter & Stay Updated
